Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $4.11 million.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.